The small intestine provides a big opportunity to transform medicine
We are discovering and developing a new class of orally delivered medicines that act on cells in the small intestine with systemic therapeutic effects. Cells in the small intestine play a central role in governing the immune, metabolic, and neurological systems.
A New Approach
Evelo’s product candidates are pharmaceutical preparations of single strains of microbes or microbial extracellular vesicles selected for their ability to modulate the immune system through SINTAX, the small intestinal axis.
SINTAX is a sensory window to the outside world. It relays messages from the small intestine to the rest of the body, which govern inflammation, as well as many other physiological functions. Evelo aims to harness this connection between the small intestine and the rest of the body to develop orally delivered medicines that act in the small intestine to exert therapeutic effects throughout the body.
In preclinical and clinical studies, we have observed that our product candidates are well tolerated with no overall difference reported from placebo. Data show that SINTAX-based medicines have meaningful clinical effects.
The potentially unique profile of SINTAX medicines could allow us to achieve our vision of providing a new class of effective, safe and well-tolerated, oral and convenient, affordable medicines to hundreds of millions of people at all stages of inflammatory disease.
Our platform and product candidates have the potential to target diseases ranging from inflammatory conditions such as psoriasis, atopic dermatitis, asthma, arthritis, inflammatory bowel disease, and food allergy, to neurogenerative conditions such as multiple sclerosis, and possibly Parkinson’s and Alzheimer’s disease.
Mechanism of Action
The Next Wave
In order to capture the full potential of SINTAX medicines across different biologies and diseases, we are also advancing microbial extracellular vesicles (EVs) as our next generation of product candidates. Currently in preclinical development, Evelo has seen positive effects of pharmaceutical preparations of bacterial EVs from single strains, delivered orally.
The promise of extracellular vesicles
Learn More About SINTAX
What is SINTAX?
How do we know SINTAX medicines work?
What is the mechanism of action?
Patent Portfolio
Our IP estate provides several layers of protection for our therapies. We have multiple issued patents and many pending patent applications covering our product candidates and platform technology. Our current patent estate is expected, based on the particular patent or application, to provide patent protection that will expire between the late 2020s and early 2040s.
Contact Us
We Want to Hear From You
Let’s start the conversation. For inquiries or requests for more information, reach out.
